The coronavirus disease has resulted in huge public interest in a process that is usually restricted to the research departments of pharma companies, laboratories and research institutions, and peer-reviewed academic journals with readership in the thousands (or tens of thousands).
Posted from: this blog via Microsoft Flow.
No comments:
Post a Comment